36 results about "N-methylacetamide" patented technology

Stable water based High-Temperature-High-Pressure (HTHP) and / or Non-HTHP crosslinked copolymers for oil and gas applications consist of (i) a crosslinked, linear polyvinyl amide / polymerizable carboxylic acid) copolymer, having a composition, by weight, of 25-75 wt. % of a vinyl amide monomer selected from vinyl pyrrolidone, vinyl caprolactam, N-vinyl-N-methylacetamide and mixtures thereof, and 25-75 wt. % of a polymerizable carboxylic acid monomer selected from acrylic acid, (meth)acrylic acid, crotonic acid, itaconic acid, maleic acid and mixture thereof; and (ii) a crosslinker in an amount of 0.01-5% based on weight of total monomers. Also discloses relevant compositions comprising said copolymer and method of use thereof.

The invention discloses a pyrrole ring containing hemifumarate which serves as a proton pump inhibitor as well as an intermediate and pharmaceutical application thereof, and particularly discloses a pyrrole ring containing 2-(3-((2-(2-fluorophenyl)-4-((methylamino)methyl)-1H-pyrrol-1-yl)sulfonyl)phenoxy)-N-methylacetamide hemifumarate which serves as a proton pump inhibitor and has a formula (I) as shown in the specification, a method for synthesizing the same from 2-(3-((2-(2-fluorophenyl)-4-((methylamino)methyl)-1H-pyrrol-1-yl)sulfonyl)phenoxy)-N-methylacetamide and fumaric acid and an preparation intermediate of the 2-(3-((2-(2-fluorophenyl)-4-((methylamino)methyl)-1H-pyrrol-1-yl)sulfonyl)phenoxy)-N-methylacetamide hemifumarate. The pyrrole ring containing 2-(3-((2-(2-fluorophenyl)-4-((methylamino)methyl)-1H-pyrrol-1-yl)sulfonyl)phenoxy)-N-methylacetamide hemifumarate disclosed by the invention has good stability, excellent biological activity and a good gastric acid inhibition effect.

The invention relates to a preparation method of ultra-high crosslinking type adsorptive resin modified by N-methyl acetamido. Lewis acid is added into a chlorine ball swollen in a solvent to be as a catalyst, and Friedel-Crafts reaction is carried out at 80 to 100 DEG C so as to obtain the ultra-high crosslinking type adsorptive resin; and the obtained resin is further aminated and acetylated soas to prepare the ultra-high crosslinking type adsorptive resin modified by the N-methyl acetamido. According to the preparation method of the ultra-high crosslinking type adsorptive resin modified by the N-methyl acetamido, the surface of the ultra-high crosslinking type adsorptive resin is loaded with the N-methyl acetamido, which can obviously enhance the adsorption capacity of the resin to weak polar and polar substances (such as phenol and salicylic acid). The ultra-high crosslinking type adsorptive resin modified by the N-methyl acetamido has an extensive application prospect in the fields of the treatment, the recycle and the like of phenols and organic acid wastewater.

The invention belongs to the field of gas purification and provides a novel absorption solution for removing H2S, COS, mercaptan, thioether and other sulfides, as well as CO2 from natural gas. The absorption solution contains a hindered amine, an alcohol amine, N-methylacetamide, a salt type catalyst and deionized water, wherein the concentration of the alcohol amine is 15-40% (wt), and the concentration of the hindered amine is 10-60% (wt); the hindered amine can be a single steric hindered amine or a mixture of a variety of steric hindered amines, and the hindered amine is a non-linear alcohol amine type compound bringing one or more steric hindered structures on nitrogen atoms; the concentration of the N-methylacetamide is 5-30% (wt); the concentration of the salt type catalyst is 0.1-5%. Compared with a traditional alcohol amine solvent, the absorption solution provided by the invention has the significant advantages of high desulfurization rate, low energy consumption for regeneration, good stability, cheap price and the like.

A composition is provided herein for preventing or retarding the formation of gas hydrates or for reducing the tendency of gas hydrates to agglomerate, during the transport of a fluid comprising water and a hydrocarbon, through a conduit. The composition is a homopolymer of an N-alkyl(meth)acrylamide, N,N-dialkyl(meth)acrylamide or copolymers thereof with N-vinyl-N-methylacetamide, in a defined solvent, which homopolymers and copolymers are made and applied in the defined solvent, which, most preferably, is a low molecular weight glycol ether such as 2-butoxyethanol.

The invention relates to a preparation method of a polyvinylidene fluoride / graphene oxide composite ultrafiltration membrane. The method comprises steps as follows: (1), graphene oxide with certain mass is weighed accurately, dispersed in an N,N-methyl acetamide solution and subjected to ultrasonic treatment for at least 10 h, and a fully stripped dispersion liquid is obtained; (2) polyvinylidene fluoride powder is stirred to be dissolved in the N,N-methyl acetamide solution at the temperature of 70 DEG C, the graphene oxide dispersion liquid and a polyvinylidene fluoride membrane casting liquid are mixed, stirred for 24 h and subjected to ultrasonic treatment for 2 h; (3) the membrane casting liquid is placed in a vacuum environment for full degasing, 200 mu m of the membrane casting liquid is accurately applied to a glass plate in certain size through a membrane scraper, the glass plate stays in the air for 20 s and is immersed in a coagulating bath which is deionized water at the temperature of 20 DEG C, and the phase conversion process is finished; (4) a prepared composite membrane is cleaned for removal of residual solvent. A polyvinylidene fluoride membrane material is modified, so that the application performance of the membrane is improved.

The invention provides a novel preparation method for a selective kinases inhibitor Palbociclib for cyclin-dependent kinases CDK4 and CDK6, and belongs to the technical field of medicament preparation. The preparation method comprises taking 4-amino-5-bromo-2-chloropyrimidine as an initial raw material, performing acetylation with N-methoxy-N-methylacetamide to obtain an intermediate 2, performing Friedlaender reaction on the intermediate and a raw material ethyl acetoacetate to obtain an intermediate 3, and performing amino substitution on the intermediate 3 and a halogenated cyclopentane to obtain an intermediate 4; performing substitution reaction on a raw material 5-bromo-2-nitropyridine and a raw material tert-butyl 1-piperazinecarboxylate to obtain an intermediate 5, and reducing the intermediate 5 to obtain an intermediate 6; performing substitution reaction on the intermediate 4 and the intermediate 6, and performing deprotection to obtain the target product 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one with the yield of 45% or more. A brand-new route is employed, the reaction raw materials are cheap and easy to obtain, reaction conditions are mild, noble metal catalysts are avoided, and the preparation method is suitable for industrialized production.

The invention relates to a corrosion-resistant elevator color-coated sheet. The corrosion-resistant elevator color-coated sheet is sequentially provided with a surface coating, a bottom coating, a passivation layer and a base sheet layer from top to bottom. The surface coating comprises, by weight, 100 parts of epoxy resin, 20-22 parts of acetylene-butyl acrylate copolymer, 5-6 parts of octyl benzoate and 5-6 parts of n-methylacetamide. The bottom coating comprises, by weight, 100 parts of polyurethane resin, 9-10 parts of borax, 4-5 parts of sodium silicate, 10-12 parts of propylene-styrol copolymer, 2-3 parts of gamma-lactam and 2-3 parts of hexamethyl-disilazane. According to the scheme, a traditional elevator color-coated sheet is modified, and various modifying materials are introduced to improve the structure toughness, the surface strength, the corrosion resistance and the scratch resistance of the coatings.

The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).

The invention provides a method for preparing ethylmethylamino formyl chloride, which comprises the steps of: taking N-methylacetamide or N-ethylformamide as a raw material, performing a reduction reaction with a reducing agent and Lewis acid at a reflux temperature of an organic solvent (1) in the organic solvent (1) to obtain N-ethyl methyl amine, and reacting the N-ethyl methyl amine and triphosgene or phosgene to obtain the ethylmethylamino formyl chloride, wherein the organic solvent (1) is a mixed solution of methylbenzene, benzene and tetrahydrofuran or a mixed solution of the methylbenzene and the tetrahydrofuran; the reducing agent is KBH4, NaBH4, LiAlH4, Pd / C or an 45 percent BF3 / ether solution; the Lewis acid is one of zinc chloride, ferric trichloride or aluminum trichloride; and the molar ratio of the N-methylacetamide or the N-ethylformamide to the reducing agent to the Lewis acid is 1: 1.01-2.0: 1.01-1.8. The method has the advantages of easy reaction of the whole road,short road, raw and auxiliary material conservation, low production cost and the like, and is favorable for industrialized production.

The present invention provides double stranded compositions wherein one of the strands is useful in, for example, influencing the preferential loading the opposite strand into the RISC (or cleavage) complex. In particular, the present invention provides oligomeric compounds that comprise chemical modifications in at least one of the strands to drive loading of the opposite strand into the RISC (or cleavage) complex. Such modifications can be used to increase potency of duplex constructs that have been modified to enhance stability. Examples of chemical modifications that drive loading of the second strand include, but are not limited to, MOE (2′-O(CH2)2OCH3), 2′-O-methyl, -ethyl, -propyl, and —N-methylacetamide. Such modifications can be distributed throughout the strand, or placed at the 5′ and / or 3′ ends to make a gapmer motif on the sense strand. The activity of the 4′-thio gapmer RNA antisense strand can be improved by incorporating alternating MOE or MOE gapmer motif into the sense strand.

The invention relates to the technical field of extraction of alkaline / non-alkaline nitrogen from simulated gasoline, and discloses a low eutectic solvent and a method for extracting the alkaline / non-alkaline nitrogen from the simulated gasoline. The low eutectic solvent for extracting the alkaline / non-alkaline nitrogen from the simulated gasoline is prepared by heating a hydrogen bond receptor and a hydrogen bond donor according to a molar ratio of 1:1 while stirring, and performing a reaction, wherein the hydrogen bond receptor is N-methylacetamide or N-methylformamide and the hydrogen bonddonor is 2,3-dibromopropionic acid or 2,3-dichloropropionic acid. When the low eutectic solvent is used for extracting the alkaline / non-alkaline nitrogen from the simulated gasoline, the extracting efficiency is high and the using amount of an extracting agent is low, so that achievement of industrialization of extraction of the non-alkaline nitrogen from the gasoline through the low eutectic solvent becomes possible.

A process for preparing N-methylacetylamine from acetic acid and methylamine includes such steps as aminating, evaporating water, evaporating acid, and fractionating. Its advantage is no corrosion to apparatus.

The invention belongs to the field of nonionic monomer X-ray contrast agents, and relates to a triiodo-benzene compound contrast agent with excellent physicochemical properties and a preparation method of the compound. The compound is N,N-dimethyl-N'-(2,3-dihydroxy-n-propyl)-5-(N-methylacetamido)-2,4,6-triiodo-1,3-isophthalamide.

The invention provides a preparation method of a key intermediate 1-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-chloroethanone. The method comprises the steps as follows: 2-amino-5-bromobenzoic acid is taken as a raw material, and subjected to diazotization, iodination,synthesis of 5-bromo-2-iodobenzoic acid, methylation, coupling reaction with phenylboronic acid, ester hydrolysis, acyl chlorination,intramolecular Friedel-Crafts alkylation, carbonyl reduction, iodization, fluorination and final reaction with 2-chloro-N-methoxy-N-methylacetamide to prepare the target product. The process adopts easily available starting raw materials, is low in price and free of hazardous process and has mild reaction conditions..

The present invention relates to a method for producing N-methyl-N-vinylacetamide, which comprises a step for controlling the N-1,3-butadienyl-N-methylacetamide content in N-methyl-N-vinylacetamide to 0.01-150 ppm. This method enables production of N-methyl-N-vinylacetamide having a stable quality, which can be controlled in stability and polymerizability as a monomer. N-methyl-N-vinylacetamide produced by the method enables production of an N-methyl-N-vinylacetamide polymer having stable physical properties such as a molecular weight.

The invention discloses a method for preparing N,N-dimethylacetylamide. The method comprises the following steps: by taking formaldehyde, formic acid and N-methylacetamide as raw materials, firstly, enabling formaldehyde to react with the formic acid to form an active intermediate under a catalyst and the heating condition; secondly, enabling the generated active intermediate to react with the N-methylacetamide, so as to form the N,N-dimethylacetylamide; finally, obtaining the N,N-dimethylacetylamide from the product by the processes of centrifuging, filtering, vacuum distillation and the like. The method is short in preparation flow, and low in reaction temperature, and has the advantages of being low in temperature, environmental, and short in flow, and the problem of environmental pollution in the preparation process is avoided.

To provide a hydrochloride of a tricyclic pyrazolopyrimidine compound inhibiting the effect of HSP90 and a crystal thereof. The present invention provides a hydrochloride of 2-{4-amino-2-[(3-chloro-4-methoxy-5-methylpyridin-2-yl)methyl]-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo[cd]azulen-8-yl}-N-methylacetamide which inhibits the ATPase activity of HSP90 and which has antitumor activity, a crystal thereof, a medicament comprising the same, an anticancer agent comprising the same, and the like.

A method for inhibiting the formation of clathrate hydrates in a fluid having hydrate forming constituents is claimed. More specifically, the method can be used in treating a petroleum fluid stream such as natural gas conveyed in a pipe to inhibit the formation of a hydrate restriction in the pipe. The hydrate inhibitors used for practicing the method comprise substantially water soluble polymers having N-vinyl amide or N-allyl amide units. Each N-vinyl amide and N-allyl amide unit has two substituent groups, R1 and R2, substituted on the nitrogen where R1 is a hydrogen or hydrocarbon group having one to six carbon atoms and zero to two heteroatoms selected from the group consisting of oxygen, nitrogen, and combinations thereof, where R2 is a hydrocarbon group having one to six carbon atoms and zero to two heteroatoms selected from the group consisting of oxygen, nitrogen, and combinations thereof, and where the sum total of carbon atoms in R1 and R2 is greater than or equal to one, but less than eight. Some preferred examples of such polymers include copolymers of N-vinyl amides and substituted acrylamides. Specific examples of such copolymers include, N-vinyl-N-methylacetamide (VIMA) copolymerized with acryloylpyrrolidine (APYD) or acryloylpiperidine (APID), and more preferably, VIMA copolymerized with N-substituted methacrylamides, such as N-isopropylmethacrylamide (iPMAM) and methacryloylpyrrolidine (MAPYD) to produce inhibitors for practicing the claimed method.

To provide a hydrochloride of a tricyclic pyrazolopyrimidine compound inhibiting the effect of HSP90 and a crystal thereof. The present invention provides a hydrochloride of 2-{4-amino-2-[(3-chloro-4-methoxy-5-methylpyridin-2-yl)methyl]-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo[cd]azulen-8-yl}-N-methylacetamide which inhibits the ATPase activity of HSP90 and which has antitumor activity, a crystal thereof, a medicament comprising the same, an anticancer agent comprising the same, and the like.

The invention relates to a static spinning preparation method for a polyvinyl pyrrolidone / biphenylalanine composite nano-fiber film. The method comprises the steps of: (1) slowly adding the polyvinyl pyrrolidon and the biphenylalanine into a mixing solvent of carbinol and N, N-methylacetamide along with agitating, and continuously agitating for 20 to 30 minutes until the mixture is completely swelled; and then vibrating for 15 to 24 hours at 25 plus or minus 2 DEG C until the mixture is dissolved completely so as to obtain the transparent polymer solution, and ultrasonically processing the transparent polymer solution for 15 minutes to degas so as to obtain spinning solution; and (2) statically spinning the obtained spinning solution to obtain a film, and then drying the film in vacuum to obtain the finished product. According to the method, the operation is simple, and less time is consumed, and the raw materials are cheap and easy to obtain; by adopting the method, the film material with diameter and aperture at nanometer level can be obtained; and the method is suitable for large-scale production.

The present invention provides an agent for the prophylaxis or treatment of substance abuse and dependence, which contains a compound of the formula (I) represented by (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).